47.38
-1.46 (-2.99%)
| Previous Close | 48.84 |
| Volume | 21,416,811 |
| Price / Earnings (Forward) | 23.64 |
| Price / Sales | 8.09 |
| Price / Book | 3.68 |
| 52 Weeks Range |
| Profit Margin | 17.97% |
| Operating Margin (TTM) | 27.38% |
| Diluted EPS (TTM) | 0.850 |
| Quarterly Revenue Growth (YOY) | 18.30% |
| Quarterly Earnings Growth (YOY) | 63.90% |
| Total Debt/Equity (MRQ) | 10.86% |
| Current Ratio (MRQ) | 2.73 |
| Operating Cash Flow (TTM) | 5.22 B |
| Levered Free Cash Flow (TTM) | -2.30 B |
| Return on Assets (TTM) | 5.05% |
| Return on Equity (TTM) | 8.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | WUXI BIO | - | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -0.44 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| WUXI BIO | - | - | - | 3.68 |
| INNOVENT BIO | - | - | - | 7.57 |
| SBP GROUP | - | 1.15% | - | 2.47 |
| AKESO | - | - | - | 8.83 |
| INNOCARE | - | - | - | 2.86 |
| KEYMED BIO-B | - | - | - | 5.00 |
|
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing, refining, and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Core |
| % Held by Insiders | 13.07% |
| % Held by Institutions | 35.91% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |